This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
by Kinjel Shah
NVO's novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY's Zepbound for sleep apnea.
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
by Zacks Equity Research
SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.
Should Value Investors Buy Pfizer (PFE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?
by Sundeep Ganoria
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
by Kinjel Shah
PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.
Why Pfizer (PFE) Dipped More Than Broader Market Today
by Zacks Equity Research
Pfizer (PFE) concluded the recent trading session at $25.77, signifying a -0.46% move from its prior day's close.
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations
by Zacks Equity Research
Pfizer projects total revenues between $61.0 and $64.0 billion with EPS in the range of $2.80 to $3.00.
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
by Zacks Equity Research
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
by Zacks Equity Research
Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $25.23, marking a -1.33% move from the previous day.
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
by Zacks Equity Research
The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
by Zacks Equity Research
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
by Zacks Equity Research
uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
by Zacks Equity Research
Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.
Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?
by Ekta Bagri
Bristol Myers stock has witnessed a stupendous rally in the past six months. We believe there is more room for growth, and any dip in the share price can be used as a buying opportunity.
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
by Zacks Equity Research
EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, reni-cel, for severe SCD.
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
by Zacks Equity Research
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyo's Dato-DXd for previously treated advanced EGFR-mutated NSCLC.
Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%
by Zacks Equity Research
LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
by Zacks Equity Research
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
PFE or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
by Zacks Equity Research
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.